International Gardian

International Gardian is a UK private company established to own and govern GARDIAN, a patient-led global registry focused on neuronopathic Gaucher disease. The company appears to operate as a healthcare data and registry vehicle rather than as a traditional drug-development biotech, with its activities centered on collecting retrospective and prospective clinical outcomes and patient-reported data. It is wholly owned by the International Gaucher Alliance and supports real-world evidence generation intended to improve disease understanding, inform clinical trial design, and accelerate diagnosis and care. Available public information does not indicate that International Gardian develops proprietary therapeutics or has a conventional drug pipeline.